Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24172307 | 0.84 | CA12 (0.39) | CA14HDAC6HDAC1HDAC2CA12 | |
| SCHEMBL21937996 | 0.82 | CA14 (0.41) | CA14HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL14157489 | 0.82 | CA14 (0.58) | TDP1CA14HDAC6HDAC1HDAC2 | |
| SCHEMBL3750380 | 0.82 | TDP1 (0.43) | TDP1CA14HDAC6HDAC1HDAC2 | |
| SCHEMBL8887438 | 0.81 | HDAC1 (0.40) | CA14HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL9434880 | 0.81 | HDAC6 (0.44) | TDP1CA14HDAC6HDAC1HDAC2 | |
| SCHEMBL1094425 | 0.80 | TDP1 (0.42) | TDP1CA14HDAC6HDAC1HDAC2 | |
| SCHEMBL1222571 | 0.79 | HDAC6 (0.36) | CA14HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL9901110 | 0.79 | CA14 (0.44) | CA14HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL15571120 | 0.79 | CA14 (0.42) | TDP1CA14HDAC6HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219881-A1 | Synthesis of Spermidine, Spermine, and Free Bases Thereof | Compound Solutions Inc. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | disclosed |
| EP-1653961-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080255143-A1 | Inhibitors of Akt Activity | SMITHKLINE BEECHAM CORPORATION (PA) | 2008-10-16 | — | — | US | disclosed |
| EP-1653961-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005011700-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD5, ENTPD1, SLC29A1 | TDP1 362/4885CA14 4547/4885HDAC6 4322/4885 |
| US-20080255143-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | TDP1 751/4885CA14 4739/4885HDAC6 715/4885 |
| US-20230219881-A1 | Synthesis of Spermidine, Spermine, and Free Bases Thereof | SRM, SMS, SMOX | TDP1 1335/4885CA14 3137/4885HDAC6 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.